Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of the American Medical Association (JAMA)

• Publication date

  2016-04-19

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/jama.2016.4059PMID 27092830
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

  2015cited by this paper
• Pembrolizumab versus Ipilimumab in Advanced Melanoma.

  2015cited by this paper
• Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.

  2015cited by this paper
• Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

  2015cited by this paper
• Pembrolizumab for the treatment of non-small-cell lung cancer.

  2015cited by this paper
• Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.

  2014cited by this paper
• Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.

  2014cited by this paper
• 1085OSURVIVAL, RESPONSE DURATION, AND ACTIVITY BY BRAF MUTATION (MT) STATUS IN A PHASE 1 TRIAL OF NIVOLUMAB (ANTI-PD-1, BMS-936558, ONO-4538) AND IPILIMUMAB (IPI) CONCURRENT THERAPY IN ADVANCED MELANOMA (MEL).

  2014cited by this paper
• Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors

  2014cited by this paper
• Randomized comparison of two doses of the anti-PD-1 monoclonal antibody MK-3475 for ipilimumab-refractory (IPI-R) and IPI-naive (IPI-N) melanoma (MEL).

  2014cited by this paper
• Baseline tumor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475.

  2014cited by this paper
• Do BRAF inhibitors select for populations with different disease progression kinetics?

  2013cited by this paper
• Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

  2013cited by this paper
• Future perspectives in melanoma research: meeting report from the “Melanoma Bridge”: Napoli, December 3rd–6th 2014

  2013cited by this paper
• Future perspectives in melanoma research. Meeting report from the “Melanoma Bridge. Napoli, December 2nd-4th 2012”

  2013cited by this paper
• The blockade of immune checkpoints in cancer immunotherapy

  2012cited by this paper
• Tumor immunotherapy directed at PD-1.

  2012cited by this paper
• New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

  2009cited by this paper
• Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

  2009cited by this paper
• PD-1 and PD-1 ligands: from discovery to clinical application.

  2007cited by this paper
• Restoring function in exhausted CD8 T cells during chronic viral infection

  2006cited by this paper
• PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells

  2004cited by this paper
• THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL

  1934cited by this paper

• High-Grade Immune-Related Adverse Events Resulting from Immune Checkpoint Inhibitor Treatment: Evaluation of Diagnostics and Outcomes in Admitted Patients

  2026cites this paper
• RAS/MEK/PI3K pathway inhibition augments response to CD40 agonism by targeting CD11b+ Bregs thereby overcoming melanoma PD1-resistance

  2026cites this paper
• Characterizing the Head and Neck Cancer Microenvironment: Implications for Immunotherapy and Prognosis.

  2026cites this paper
• Computational screening of Viola odorata cyclotides identifies Phyb C as potential PD-1 inhibitor for cancer immunotherapy.

  2026cites this paper
• Prognostic Significance of the Modified Glasgow Prognostic Score in Patients With Stage IV Melanoma Receiving Immune Checkpoint Inhibitors: A Single-Center Retrospective Study.

  2026cites this paper
• Fully human anti-B7-H4 antibody induces lysosome-dependent ferroptosis to reverse primary resistance to PD-1 blockade

  2026cites this paper
• Safety of Multi-Omics-Guided Therapy in Advanced Melanoma: A Matched Comparative Cohort Analysis.

  2026cites this paper
• Pharmacological strategies to overcome immune checkpoint inhibitor resistance in non-small cell lung cancer

  2026cites this paper
• Engineering bispecific exosome activators of T cells to target immune checkpoint inhibitor-resistant metastatic melanoma.

  2026cites this paper
• The combination of CD8 and TIM3 expression predicts survival outcomes in hepatocellular carcinoma.

  2025cites this paper
• Biomarker-informed care for patients with renal cell carcinoma

  2025cites this paper
• Activating the CXCR3/CXCL10 pathway overrides tumor immune suppression by enhancing immune trafficking and effector cell priming in head and neck squamous cell carcinoma

  2025cites this paper
• RP1 Combined With Nivolumab in Advanced Anti–PD-1–Failed Melanoma (IGNYTE)

  2025cites this paper
• A Comparative Analysis Dissecting the Immune Landscape of Vitiligo and Melanoma from a single-cell Perspective: Two Sides of the Same Coin?

  2025cites this paper
• Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naive Advanced Melanoma.

  2025cites this paper
• Aptamer‐Engineered Ellipsometry for Clinical Detection of BALF‐Derived Exosomes: Multi‐Level Engineering for Prognostic Evaluation of Immunotherapy Responses

  2025cites this paper
• A gut-on-a-chip incorporating human faecal samples and peristalsis predicts responses to immune checkpoint inhibitors for melanoma

  2025cites this paper
• Oncolytic virus OH2 extends survival in patients with PD-1 pretreated melanoma: phase Ia/Ib trial results and biomarker insights

  2025cites this paper
• Integration of multiple machine learning approaches develops a gene mutation-based classifier for accurate immunotherapy outcomes

  2025cites this paper
• Distinct cellular mechanisms underlie chemotherapies and PD-L1 blockade combinations in triple-negative breast cancer.

  2025cites this paper
• International real-world study of combination immunotherapy sequences in metastatic melanoma

  2025cites this paper
• Nuevas posibilidades terapéuticas en melanoma metastásico

  2025cites this paper
• Immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD-1 treatment. A EUMelaReg real-world evidence study.

  2025cites this paper
• Therapeutic potential of isochlorogenic acid A from Taraxacum officinale in improving immune response and enhancing the efficacy of PD-1/PD-L1 blockade in triple-negative breast cancer

  2025cites this paper
• The Society for Immunotherapy of Cancer Perspective on Liquid Biopsy and Radiomics Based Technologies for Immuno-Oncology Biomarker Discovery and Application.

  2025cites this paper
• Correlation between irAEs and survival outcomes in patients with ES-SCLC treated with first-line chemoimmunotherapy.

  2025cites this paper
• Long-Term Efficacy and Safety of Lifileucel Tumor-Infiltrating Lymphocyte Cell Therapy in Patients With Advanced Melanoma: A 5-Year Analysis of the C-144-01 Study

  2025cites this paper
• Recent Advances in Cancer Treatment: Immunotherapy vs Chemotherapy

  2025cites this paper
• Uncovering prognostic biomarkers through a pharmacovigilance study: the case of RDW

  2025cites this paper
• Serum metabolic profiling enables diagnosis, prognosis, and monitoring for brainstem gliomas

  2025cites this paper
• “Dissecting the role of T cell exhaustion in cancer progression: a multifaceted approach“

  2025cites this paper
• Targeting immune checkpoint therapy: The role of manganese in tumor immunotherapy.

  2025cites this paper
• Ultrasound-Stimulated Microbubble Cavitation Combined With Anti-PD-L1 Blockade Inhibits the Progression of MC38 Tumors and Alters the Composition of Gut Microbiota in Mice

  2025cites this paper
• Physical examinations and whole-body imaging versus physical examinations alone during follow-up after radical surgery of stage IIB-C and III cutaneous malignant melanoma (TRIM): an interim analysis of a multicentre, randomised, phase 3 trial in Sweden.

  2025cites this paper
• Beyond Binary: A Machine Learning Framework for Interpreting Organismal Behavior in Cancer Diagnostics

  2025cites this paper
• The role of circadian genes in predicting immunotherapy response and survival outcomes in cancer patients

  2025cites this paper
• Probing and enhancing tumor-infiltrating lymphocytes: insights from single-cell technologies and genetic reprogramming

  2025cites this paper
• Inhibition of PD-L1/PD-1 Checkpoint Increases NK Cell-Mediated Killing of Melanoma Cells in the Presence of Interferon-Beta

  2025cites this paper
• Anti-CTLA-4 generates greater memory response than anti-PD-1 via TCF-1

  2025cites this paper
• Avances en medicina traslacional para el manejo del melanoma: Una revisión narrativa

  2025cites this paper
• Combined PARP14 inhibition and PD-1 blockade promotes cytotoxic T cell quiescence and modulates macrophage polarization in relapsed melanoma

  2025cites this paper
• Recurrent and Metastatic Head and Neck Cancer: Mechanisms of Treatment Failure, Treatment Paradigms, and New Horizons

  2025cites this paper
• Polyradiculoneuropathies associated with immune checkpoint inhibitors: are we facing a new nosological entity?

  2025cites this paper
• Managing Biologic Therapy and Small Molecule Use in IBD Patients during and after Cancer Diagnosis

  2025cites this paper
• Aptamers Targeting Immune Checkpoints for Tumor Immunotherapy

  2025influential citation
• Dermatologic Oncology: The Past 50 Years.

  2025cites this paper
• Mechanisms of Resistance to Anti-PD-1 Immunotherapy in Melanoma and Strategies to Overcome It

  2025cites this paper
• Case report: Low-dose radiation reverses pembrolizumab resistance in melanoma

  2025cites this paper
• FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma.

  2025cites this paper
• High baseline levels of PD-L1 reduce the heterogeneity of immune checkpoint signature and sensitize anti-PD1 therapy in lung and colorectal cancers

  2025cites this paper
• An interpretable machine learning model based on computed tomography radiomics for predicting programmed death ligand 1 expression status in gastric cancer

  2025cites this paper
• Anti-CTLA-and anti-PD-1 immune checkpoint inhibitor antibodies impair human sperm motility in-vitro

  2025cites this paper
• Longitudinal Evaluation of Immune Checkpoint Inhibitor‐Induced Fatigue Syndrome by Rest, Stress, and Speckle‐Tracking Strain Echocardiography

  2025cites this paper
• Primary Malignant Melanoma of the Uterine Cervix with S100 (Protein Marker Seen in Women with Melanoma) Negative Status and Novel ATM Gene Mutation: Case Report and Literature Review

  2025cites this paper
• Effective TIL Therapy for Patients with Checkpoint-Resistant Melanoma without Lymphodepleting Regimens Requires IFNα

  2025cites this paper
• Ultrasound Visualization of Spatiotemporal Autophagy-Regulated Nanodroplets for Amplifying ICB in Melanoma via Remodeling Tumor Inflammatory Microenvironment

  2025cites this paper
• Semaphorin7A and PD-L1 cooperatively drive immunosuppression during mammary involution and breast cancer

  2025cites this paper
• Regulatory Mechanisms and Therapeutic Targeting of PD-L1 Trafficking and Stability in Cancer Immunotherapy

  2025cites this paper
• Recent Advances in Molecular Research and Treatment for Melanoma in Asian Populations

  2025cites this paper
• Tumor Cell–Intrinsic Decr2 Regulates Ferroptosis and Immunotherapy Efficacy

  2025cites this paper
• Posttranslational remodeling micelle reverses cell-surface and exosomal PD-L1 immunosuppression in tumors resistant to PD-L1 antibody therapy.

  2025cites this paper
• Integrative Molecular and Immune Profiling in Advanced Unresectable Melanoma: Tumor Microenvironment and Peripheral PD-1+ CD4+ Effector Memory T-Cells as Potential Markers of Response to Immune Checkpoint Inhibitor Therapy

  2025cites this paper
• Changes in prescribing patterns and access to immune checkpoint inhibitors in german lung cancer patients – a claims data analysis

  2025cites this paper
• Disparities in utilization of novel cancer therapies in advanced stage III and IV melanoma and variance in outcomes.

  2025cites this paper
• Vinburnine potentiates anti-PD1 immunotherapy in melanoma through IL-24 secretion via P38/MAPK/ATF3 signaling

  2025cites this paper
• Anti-Cancer Effects of PD-L1 Targeted Immunotherapy in Oral Squamous Cell Carcinoma Animal Models

  2025cites this paper
• Oncolytic viruses as anticancer agents: clinical progress and remaining challenges.

  2025cites this paper
• Fusing Oncolytic Virotherapy With Cancer Immunotherapy to Treat Therapy-Resistant Melanoma.

  2025cites this paper
• Fecal microbiota transplantation to enhance cancer treatment outcomes across different cancer types: A systematic literature review.

  2025cites this paper
• Inhibition of ICAM1 diminishes stemness and enhances antitumor immunity in glioblastoma via β-catenin/PD-L1 signaling

  2025cites this paper
• Immunotherapy for precision medicine in colorectal cancer

  2025cites this paper
• Impact of neoadjuvant immunotherapy on postoperative complications in oncoplastic breast cancer surgery.

  2025cites this paper
• Avances presentes y futuros en el tratamiento de melanoma cutáneo

  2024cites this paper
• Connection Between HIV and Mitochondria in Cardiovascular Disease and Implications for Treatments

  2024cites this paper
• Randomized Placebo-Controlled, Biomarker-Stratified Phase Ib Microbiome Modulation in Melanoma: Impact of Antibiotic Preconditioning on Microbiome and Immunity

  2024cites this paper
• Systematic investigation of chemo-immunotherapy synergism to shift anti-PD-1 resistance in cancer

  2024cites this paper
• Application of nanomedicines in tumor immunotherapy

  2024cites this paper
• Mi-2β promotes immune evasion in melanoma by activating EZH2 methylation

  2024influential citation
• Multidisciplinary approach and treatment of acral and mucosal melanoma

  2024cites this paper
• Automated Quantitative CD8+ Tumor-Infiltrating Lymphocytes and Tumor Mutation Burden as Independent Biomarkers in Melanoma Patients Receiving Front-Line Anti-PD-1 Immunotherapy

  2024cites this paper
• Clinical Implications of Skin Cancer in Kidney Transplant Recipients in the Era of Immune Checkpoint Inhibitors

  2024cites this paper
• Survival of patients with unfavorable prognosis cutaneous melanoma with increased use of immunotherapy agents: a population‐based study in Belgium

  2024cites this paper
• Tumor characteristics of dissociated response to immune checkpoint inhibition in advanced melanoma

  2024cites this paper
• A landscape of checkpoint blockade resistance in cancer: underlying mechanisms and current strategies to overcome resistance

  2024cites this paper
• Cross‑talk between lymphangiogenesis and malignant melanoma cells: New opinions on tumour drainage and immunization (Review)

  2024cites this paper
• Incidence of Cutaneous Immune-Related Adverse Events and Outcomes in Immune Checkpoint Inhibitor-Containing Regimens: A Systematic Review and Meta-Analysis

  2024cites this paper
• Cancer cell membrane-decorated hybrid liposomes for treating metastatic breast cancer based on enhanced cancer immunotherapy

  2024cites this paper
• Synergistic combination therapy using cowpea mosaic virus intratumoral immunotherapy and Lag-3 checkpoint blockade

  2024cites this paper
• Assessing the performance of alternative methods for estimating long-term survival benefit of immuno-oncology therapies.

  2024cites this paper
• Sarcoid-like reaction and hypothyroidism induced by PD-1 inhibitor treatment in metastatic renal cell carcinoma: a case report and literature review

  2024cites this paper
• Design Strategy and Consideration for Oncology Dose-Optimization: An Industry Perspective

  2024cites this paper
• Long‐term follow‐up results from KEYNOTE‐041: Phase 1b study of pembrolizumab in Japanese patients with advanced melanoma

  2024cites this paper
• Efficacy of immune checkpoint inhibitors differs in various status of carcinoma: a study based on 29 cohorts with 3255 participants

  2024cites this paper
• Immunological Mechanisms behind Anti-PD-1/PD-L1 Immune Checkpoint Blockade: Intratumoral Reinvigoration or Systemic Induction?

  2024cites this paper
• Overcoming Resistance Mechanisms to Melanoma Immunotherapy

  2024cites this paper
• Novel Prognostic Markers for Skin Cutaneous Melanoma

  2024cites this paper
• Validation of the graded prognostic assessment and recursive partitioning analysis as prognostic tools using a modern cohort of patients with brain metastases.

  2024cites this paper
• Into the Future: Fighting Melanoma with Immunity

  2024cites this paper
• Immune checkpoint inhibitors associated cardiovascular immune-related adverse events

  2024cites this paper
• Imaging diagnosis and efficacy monitoring by [89Zr]Zr-DFO-KN035 immunoPET in patients with PD-L1-positive solid malignancies

  2024cites this paper